首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1909112

生物製剂CDMO市场规模、份额和成长分析（按服务类型、生产平台、治疗模式、最终用户和地区划分）－2026-2033年产业预测

Biologics CDMO Market Size, Share, and Growth Analysis, By Service Type, By Production Platform, By Modality Type, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月02日 | 出版商:

SkyQuest | 英文 181 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球生物製剂 CDMO 市场规模预计在 2024 年达到 246.2 亿美元，从 2025 年的 284.6 亿美元增长到 2033 年的 907.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 15.6%。

由于包括单株抗体、疫苗和先进治疗方法在内的生物製剂需求不断增长，以及生物製药公司外包趋势日益明显，全球生物製剂CDMO市场需求持续强劲。 CDMO的专业知识和专业能力，以及临床研发管线中生物製剂数量的不断增加，加速了生物製剂的市场进入。然而，该市场也面临许多挑战，包括高额资本支出、复杂的法规环境以及部分地区熟练劳动力短缺。智慧财产权问题和整合风险也构成额外的障碍。儘管存在这些挑战，但战略合作、一次性生物反应器等技术进步以及生物製造设施的持续发展将确保该行业的持续成长，长期前景仍然乐观。

全球生技药品CDMO市场驱动因素

慢性病发病率的上升和生物製药需求的不断增长，显着推动了大规模生物製药生产的需求。随着生物相似药研发的加速推进以及生物製药公司寻求更高的营运效率，製药和生物技术产业越来越依赖受託製造厂商（CDMO）。这些合作关係使企业能够充分利用CDMO的专业知识，优化资源配置，并加速产品上市速度。这一趋势反映了企业策略的转变，即透过与CDMO合作来提高生产效率，并在竞争激烈的环境中满足生物製药行业不断变化的需求。

全球生技药品CDMO市场面临的限制因素

全球生物製药CDMO市场面临许多限制因素，主要源自于生产营运所需的大量资本投入。建造先进的基础设施、无尘室和专用设施会带来沉重的财务负担。生物製药加工工艺复杂，涉及细胞培养和纯化等诸多环节，进一步加剧了市场格局的复杂性，并要求具备熟练的劳动力、严格的管控措施以及深厚的生产技术专长。因此，资金障碍可能阻碍新的合约研发生产机构（CDMO）进入市场，而现有企业若缺乏充足的资金和资源，也难以有效拓展业务，可能阻碍整个产业的成长。

全球生技药品CDMO市场趋势

全球生物製药CDMO市场正经历着向一次性（可抛弃式）技术的广泛应用的重大转变。这些创新系统透过提高柔软性和最大限度地降低污染风险，提升了营运效率并简化了生产流程。快速换线提高了生产力，并有助于实施可扩展的生产模式，这对于多产品生产设施以及快速发展的个人化医疗和临床治疗领域尤其有利。随着生物製药生产对敏捷性和客製化的需求不断增长，一次性技术有望在塑造CDMO产业的未来中发挥关键作用。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Lonza Group Ltd.
Samsung Biologics
Catalent, Inc.
WuXi Biologics Cayman Inc.
Thermo Fisher Scientific Inc.
AGC Biologics
Boehringer Ingelheim BioXcellence
3P Biopharmaceuticals
FUJIFILM Diosynth Biotechnologies
Binex Co. Ltd.
Patheon（part of Thermo Fisher）
Recipharm AB
BioVectra Inc.
Janssen Biotechnology Services（Johnson & Johnson）
AbbVie Contract Manufacturing（AbbVie）
Charles River Laboratories（Biologics CDMO division）
Catalent Biologics（subsidiary of Catalent）
Philips-Morris Scientific Services（CDMO arm）
Celltrion Technologies Corporation
KanaBio Sciences Inc.

结论与建议

简介目录

Product Code: SQMIG35H2392

Global Biologics CDMO Market size was valued at USD 24.62 Billion in 2024 and is poised to grow from USD 28.46 Billion in 2025 to USD 90.77 Billion by 2033, growing at a CAGR of 15.6% during the forecast period (2026-2033).

The global biologics CDMO market is experiencing heightened demand driven by the increasing requirement for biologics such as monoclonal antibodies, vaccines, and advanced therapies, alongside a growing trend in biopharma companies to outsource operations. The expertise and specialized capabilities of CDMOs facilitate faster market entry for biologics, bolstered by an expanding number of biologics in clinical pipelines. However, this market faces challenges including high capital expenditures, complex regulatory environments, and limited skilled labor in some regions. Intellectual property concerns and integration risks also pose additional barriers. Despite these obstacles, the long-term outlook remains positive due to strategic partnerships, advancements in technology like single-use bioreactors, and the ongoing development of biomanufacturing facilities, ensuring sustained growth in the sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biologics CDMO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biologics CDMO Market Segments Analysis

Global Biologics CDMO Market is segmented by Service Type, Production Platform, Modality Type, End-User and region. Based on Service Type, the market is segmented into Process Development & Cell Line Development, Drug Substance Manufacturing, Drug Product / Fill-Finish & Packaging, Analytical / Testing / QC Services and End-to-End / Integrated CDMO Services. Based on Production Platform, the market is segmented into Mammalian Systems, Microbial Systems and Other Platforms. Based on Modality Type, the market is segmented into Monoclonal Antibodies (mAbs), Recombinant Proteins, Biosimilars, Cell & Gene Therapies / Viral Vectors and Other Biologics. Based on End-User, the market is segmented into Large Pharmaceutical Companies, Biotechnology / Small & Mid-Sized Biotechs, Academic & Research Institutes and Government / Public Sector Contracts. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biologics CDMO Market

The rise in chronic diseases and the growing demand for biologic products have significantly boosted the necessity for large-scale biologics manufacturing. As the development of biosimilars accelerates and biologics companies seek greater operational efficiencies, the pharmaceutical and biotechnology sectors are increasingly relying on contract development and manufacturing organizations (CDMOs). These partnerships enable companies to leverage specialized expertise, optimize resource allocation, and reduce time to market. This trend reflects a strategic shift towards collaboration with CDMOs to enhance productivity and meet the evolving needs of the biopharmaceutical landscape in an increasingly competitive environment.

Restraints in the Global Biologics CDMO Market

The Global Biologics CDMO market faces significant restraints primarily due to the considerable capital investment required for manufacturing operations. Establishing advanced infrastructure, cleanrooms, and specialized equipment demands a hefty financial commitment. The complexity of biologics processes, which encompasses intricate procedures like cell culture and purification, further complicates the landscape, necessitating skilled labor, rigorous controls, and deep expertise in manufacturing methodologies. As a result, financial barriers can inhibit new Contract Development and Manufacturing Organizations (CDMOs) from entering the market, while existing players may struggle to scale their operations effectively without sufficient financial backing and resources, hindering overall growth within the industry.

Market Trends of the Global Biologics CDMO Market

The global biologics Contract Development and Manufacturing Organization (CDMO) market is witnessing a significant shift towards the widespread adoption of single-use technologies. These innovative systems are enhancing operational efficiency by increasing flexibility and minimizing contamination risks, thereby streamlining production processes. The ability to conduct faster changeovers contributes to improved productivity, allowing companies to implement scalable production models that are particularly beneficial for multi-product facilities and the burgeoning field of personalized or clinical therapeutics. As demand for agility and customization in biologics manufacturing continues to rise, single-use technologies are poised to play a pivotal role in shaping the future of the CDMO landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Assessment
Regulatory Landscape

Global Biologics CDMO Market Size by Service Type & CAGR (2026-2033)

Market Overview
Process Development & Cell Line Development
Drug Substance Manufacturing
Drug Product / Fill-Finish & Packaging
Analytical / Testing / QC Services
End-to-End / Integrated CDMO Services

Global Biologics CDMO Market Size by Production Platform & CAGR (2026-2033)

Market Overview
Mammalian Systems
Microbial Systems
Other Platforms

Global Biologics CDMO Market Size by Modality Type & CAGR (2026-2033)

Market Overview
Monoclonal Antibodies (mAbs)
Recombinant Proteins
Biosimilars
Cell & Gene Therapies / Viral Vectors
Other Biologics

Global Biologics CDMO Market Size by End-User & CAGR (2026-2033)

Market Overview
Large Pharmaceutical Companies
Biotechnology / Small & Mid-Sized Biotechs
Academic & Research Institutes
Government / Public Sector Contracts

Global Biologics CDMO Market Size & CAGR (2026-2033)

North America (Service Type, Production Platform, Modality Type, End-User)
- US
- Canada
Europe (Service Type, Production Platform, Modality Type, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Service Type, Production Platform, Modality Type, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Service Type, Production Platform, Modality Type, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Service Type, Production Platform, Modality Type, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Lonza Group Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics Cayman Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AGC Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim BioXcellence
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
3P Biopharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Diosynth Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Binex Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Patheon (part of Thermo Fisher)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioVectra Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Biotechnology Services (Johnson & Johnson)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Contract Manufacturing (AbbVie)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (Biologics CDMO division)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent Biologics (subsidiary of Catalent)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Philips-Morris Scientific Services (CDMO arm)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celltrion Technologies Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KanaBio Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments